Indeed, based on the relevance of ROR1 expression in human cancers, cirmtuzumab was developed as a humanized antibody inhibiting Wnt-5a-ROR-induced signaling, which then entered a phase I clinical trial for CLL patients [252]. Here, ROR1 is linked to cancer.